

Supplementary Materials: Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer

Study start		$n = 150$
Death from toxicity refused participation	$n = 2$	$n = 148$
Missing sTK 1 value at baseline	$n = 9$	$n = 139$
Missing sTK1 value 48 h after treatment 1	$n = 8$	$n = 131$
Missing sTK 1 value before treatment 2	$n = 67$	$n = 64$
Missing sTK 1 value 48h after treatment 2	$n = 1$	$n = 63$
Missing sTK1 before treatment 3	$n = 4$	$n = 59$
Missing sTK values 48h after treatment 3	$n = 0$	$n = 59$
Missing sTK1 before treatment 4	$n = 1$	$n = 58$
Missing sTK values 48h after treatment 4	$n = 4$	$n = 54$

Figure S1. Explanation of missing data among 150 patients with breast cancer, initially recruited for the PROMIX study.




Figure S2. Normal quantile plot of the ratio: serum thymidine kinase 1 concentration (sTk1) 48h post/pre-treatment at cycle 1 in 131 patients with localized breast cancer subjected to neoadjuvant chemotherapy with docetaxel + epirubicin.




Figure S3. a. Bivariate analysis of serum thymidine kinase 1 concentration (sTk1) before and 48h after treatment 1 in 65 patients with post/pre-treatment ratio <1.12. $r = 0.73$; $p < 0.0001$.




Figure S3. b. Bivariate analysis of serum thymidine kinase 1 concentration (sTk1) before and 48h after treatment 1 in 66 patients with post/pre-treatment ratio >1.12. $r = 0.83$; $p < 0.0001$.